<SEC-DOCUMENT>0001171843-26-000054.txt : 20260105
<SEC-HEADER>0001171843-26-000054.hdr.sgml : 20260105
<ACCEPTANCE-DATETIME>20260105163236
ACCESSION NUMBER:		0001171843-26-000054
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20260102
FILED AS OF DATE:		20260105
DATE AS OF CHANGE:		20260105

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Boylan James P
		CENTRAL INDEX KEY:			0001953094
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39696
		FILM NUMBER:		26506892

	MAIL ADDRESS:	
		STREET 1:		C/O ENAVATE SCIENCES
		STREET 2:		2884 SAND HILL RD., STE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Compass Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001738021
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		80 GUEST STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02135
		BUSINESS PHONE:		617-500-8099

	MAIL ADDRESS:	
		STREET 1:		80 GUEST STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02135

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Olivia Ventures, Inc.
		DATE OF NAME CHANGE:	20180419
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2026-01-02</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001738021</issuerCik>
        <issuerName>Compass Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>CMPX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001953094</rptOwnerCik>
            <rptOwnerName>Boylan James P</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O COMPASS THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>80 GUEST STREET, SUITE 601</rptOwnerStreet2>
            <rptOwnerCity>BOSTON</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02135</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>5.17</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2026-01-02</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>90000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2036-01-02</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>90000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>90000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                    <footnoteId id="F2"/>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">This grant vests in full upon the earlier of (i) June 10, 2026 or (ii) the date of the next annual meeting of the Company's stockholders.</footnote>
        <footnote id="F2">The Reporting Person is a member of Enavate Sciences, LP (&quot;Enavate&quot;). Pursuant to an agreement with Enavate, the Reporting Person is obligated to transfer any securities issued under any stock options or other awards, or the economic benefit thereof, to Enavate, which will in turn ensure that such securities or economic benefits are provided to Enavate</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Neil Lerner, attorney-in-fact</signatureName>
        <signatureDate>2026-01-05</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
